WC
PLX icon

Woodstock Corp’s Protalix BioTherapeutics PLX Stock Holding History

Woodstock Corp’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,300
Closed -$105K – 170
2014
Q1 		$105K Buy
+2,300
New +$107K 0.02% 173

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Woodstock Corp's PLX Position: Q2 2014 in Review

Woodstock Corp sold out of Protalix BioTherapeutics (PLX) in Q2 2014, closing a stake of 2,300 shares — an estimated $105K sold.

Woodstock Corp first reported a position in PLX in Q1 2014 and held it in 1 quarter. The position peaked at $105K in Q1 2014. 45 funds tracked by Wall St. Rank hold PLX as of Q2 2014.

  • Woodstock Corp reported no remaining Protalix BioTherapeutics position as of Q2 2014 after selling out during the quarter.
  • Woodstock Corp sold 2,300 Protalix BioTherapeutics shares in Q2 2014, an estimated $105K.
  • Woodstock Corp first reported a position in Protalix BioTherapeutics in Q1 2014 and held it in 1 quarter.
  • Woodstock Corp's Protalix BioTherapeutics position peaked at $105K in Q1 2014.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2014.

Based on Woodstock Corp's 13F filing for Q2 2014, filed 7 Jul 2014.